Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.

Autor: Tran A; Pôle appareil digestif, Hôpital l'Archet 2, CHU Nice, Route Saint-Antoine de Ginestière - BP 3079, 06202 Nice Cedex 3, Nice, France. Electronic address: albert.tran@unice.fr., Shili-Masmoudi S; Service d'hépato-gastroentérologie, Hôpital Haut-Lévêque, CHU Bordeaux, pessac & INSERM U1053, Université de Bordeaux, Bordeaux, Nice, France., Moga L; Service d'Hépatologie, Hôpital Beaujon, APHP, Clichy, Nice, France., Chevaliez S; Service de bactériologie - virologie, Hôpital Henri-Mondor, APHP, Créteil, Nice, France., Luciani A; Service d'imagerie médicale, Hôpital Henri-Mondor, APHP, Créteil, Nice, France., Ruiz I; Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, Créteil, Nice, France., Ganne-Carrié N; Service d'hépatologie, Hôpital Avicenne, APHP, Université Sorbonne Paris Nord, Bobigny, Nice, France., Bureau C; Service d'hépatologie, Hôpital Rangueil, CHU Toulouse, Toulouse, Nice, France., Bourlière M; Service d'hépato-gastroentérologie, Hôpital Saint Joseph & INSERM UMR 1252 IRD SESSTIM Aix Marseille Université, Marseille, Nice, France., de Lédinghen V; Service d'hépato-gastroentérologie, Hôpital Haut-Lévêque, CHU Bordeaux, pessac & INSERM U1053, Université de Bordeaux, Bordeaux, Nice, France.
Jazyk: angličtina
Zdroj: Clinics and research in hepatology and gastroenterology [Clin Res Hepatol Gastroenterol] 2022 Jan; Vol. 46 (1), pp. 101771. Date of Electronic Publication: 2021 Jul 28.
DOI: 10.1016/j.clinre.2021.101771
Abstrakt: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. Clinical care for patients with HCV-related liver disease has advanced considerably with developments in screening, diagnostic procedures to evaluate liver fibrosis and improvements in therapy with pangenotypic direct antivirals and prevention. These AFEF guidelines on the non-invasive diagnosis and follow up of chronic infection with HCV describe the optimal management of HCV positive patients with non-invasive methods in screening, in assessing viral disease and liver fibrosis and the follow-up of these patients according to the value of FibroScan®, Fibrotest® or Fibrometer®. Hepatocellular carcinoma screening must continue in patients with liver stiffness by FibroScan® ≥10 kPa or Fibrotest® >0.58 or Fibrometer® >0.78 prior to treatment initiation. After reaching sustained virologic response, patients with a measurement of liver stiffness by FibroScan®<10 kPa or Fibrotest®≤0.58 or Fibrometer®≤0.78 before treatment initiation and without liver comorbidity (alcohol consumption, metabolic syndrome, HBV co-infection etc.) no longer require specific monitoring. The role of liver biopsy is discussed in some rare situations.
(Copyright © 2021. Published by Elsevier Masson SAS.)
Databáze: MEDLINE
Externí odkaz: